☆ 4.5 Article

Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study

RMD OPEN (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Rheumatology

Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort

Elisabetta Zanatta et al.

Summary: This study found that patients with positive anti-topoisomerase I (ATA) in limited cutaneous systemic sclerosis (lcSSc) have a high risk of interstitial lung disease (ILD), although the risk of progression is lower. Careful screening for ILD is necessary in this subgroup.

RHEUMATOLOGY (2022)

添加到收藏夹

Review Rheumatology

Systemic Sclerosis-Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration-Approved Therapies in Clinical Practice

Dinesh Khanna et al.

Summary: Systemic sclerosis (SSc) has high mortality, with interstitial lung disease (ILD) being a leading cause of death. Nintedanib and tocilizumab are approved by the FDA for SSc-associated ILD treatment. However, the optimal therapeutic strategy is still uncertain, with the review proposing a practical classification based on disease severity and progression risk, discussing different treatment options.

ARTHRITIS & RHEUMATOLOGY (2022)

添加到收藏夹

Article Rheumatology

Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON

Yannick Allanore et al.

Summary: Nintedanib can reduce the decline in forced vital capacity (FVC) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) and has consistent safety profile and FVC outcomes in both short-term and long-term use.

ANNALS OF THE RHEUMATIC DISEASES (2022)

添加到收藏夹

Meeting Abstract Rheumatology

PROGRESSIVE INTERSTITIAL LUNG DISEASE IS FREQUENT ALSO IN LATE DISEASE STAGES IN SYSTEMIC SCLEROSIS PATIENTS FROM EUSTAR

A. M. Hoffmann-Vold et al.

ANNALS OF THE RHEUMATIC DISEASES (2022)

添加到收藏夹

Review Rheumatology

Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review

Corrado Campochiaro et al.

Summary: This study conducts a systematic literature review (SLR) on rituximab (RTX), tocilizumab (TCZ), nintedanib and abatacept (ABT) for the treatment of systemic sclerosis (SSc) - interstitial lung disease (ILD), and confirms the effectiveness of RTX, TCZ and nintedanib for SSc-ILD patients. It highlights the need for more data to compare combination therapy with monotherapy.

THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2022)

添加到收藏夹

Article Rheumatology

Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database

Anna-Maria Hoffmann-Vold et al.

Summary: This study utilized data from the European Scleroderma Trials And Research (EUSTAR) database to analyze the disease course, progression patterns, and predictive factors for progressive interstitial lung disease (ILD) in patients with systemic sclerosis-associated ILD (SSc-ILD). The results showed that male sex, higher modified Rodnan skin score, and reflux/dysphagia symptoms were the strongest predictive factors for forced vital capacity (FVC) decline over a 5-year period in SSc-ILD patients.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Review Rheumatology

An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years

Corrado Campochiaro et al.

Summary: New molecular mechanisms for treating systemic sclerosis (SSc) patients have emerged, with specific drugs showing potential in various clinical trials, and some have already been approved. These studies offer hope for SSc patients, with the future challenge lying in developing personalized precision medicine for SSc treatment.

ARTHRITIS RESEARCH & THERAPY (2021)

添加到收藏夹

Review Rheumatology

Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis

Rudra P. Goswami et al.

Summary: Treatment with RTX in SSc-ILD resulted in a significant improvement in both FVC and DLCO during the first year of treatment, with lower rates of infection compared to controls.

RHEUMATOLOGY (2021)

添加到收藏夹

Review Critical Care Medicine

Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease

Dinesh Khanna et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2020)

添加到收藏夹

Review Respiratory System

Predictors of progression in systemic sclerosis patients with interstitial lung disease

Oliver Distler et al.

EUROPEAN RESPIRATORY JOURNAL (2020)

添加到收藏夹

Article Rheumatology

Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study

Corrado Campochiaro et al.

RHEUMATOLOGY (2020)

添加到收藏夹

Article Critical Care Medicine

Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

Dinesh Khanna et al.

LANCET RESPIRATORY MEDICINE (2020)

添加到收藏夹

Meeting Abstract Rheumatology

TARGETING THE RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLAST VIA CYCLIN DEPENDENT KINASE INHIBITION (TRAFIC): A PHASE 1B STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE OF SELICICLIB FOR REPURPOSING IN RHEUMATOID ARTHRITIS

A. Pratt et al.

ANNALS OF THE RHEUMATIC DISEASES (2020)

添加到收藏夹

Article Rheumatology

Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study

Muriel Elhai et al.

ANNALS OF THE RHEUMATIC DISEASES (2019)

添加到收藏夹

Article Medicine, General & Internal

Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease

Oliver Distler et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Critical Care Medicine

Tracking Impact of Interstitial Lung Disease in Systemic Sclerosis in a Complete Nationwide Cohort

Anna-Maria Hoffmann-Vold et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2019)

添加到收藏夹

Review Medicine, General & Internal

Systemic sclerosis

Christopher P. Denton et al.

LANCET (2017)

添加到收藏夹

Article Rheumatology

Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis

Nicole S. Goh et al.

ARTHRITIS & RHEUMATOLOGY (2017)

添加到收藏夹

Article Rheumatology

Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis

Jingang Huang et al.

ANNALS OF THE RHEUMATIC DISEASES (2017)

添加到收藏夹

Review Rheumatology

Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis

Dinesh Khanna et al.

JOURNAL OF SCLERODERMA AND RELATED DISORDERS (2017)

添加到收藏夹

Article Rheumatology

Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) - Report from OMERACT CTD-ILD Working Group

Dinesh Khanna et al.

JOURNAL OF RHEUMATOLOGY (2015)

添加到收藏夹

Article Rheumatology

Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group

Suzana Jordan et al.

ANNALS OF THE RHEUMATIC DISEASES (2015)

添加到收藏夹

Article Rheumatology

2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative

Frank van den Hoogen et al.

ANNALS OF THE RHEUMATIC DISEASES (2013)

添加到收藏夹

Article Rheumatology

Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database

U. A. Walker et al.

ANNALS OF THE RHEUMATIC DISEASES (2007)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.